19
30
10
↑19
↓30
—10
Evidence suggests Magnesium maydecreaseInsulin.
37 studies (59 claims)
Emerging evidence
Typical effective dose 355 (250–386.25) mgacross 8 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| magnesium and zinc | Decreases - significantly decreased | insulin levels | Human | patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM) | — | The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease.cited 41× |
| magnesium oxide supplement (250 mg/day for 2 months) | Decreases - A significant reduction | insulin resistance | Human | women aged 15-35 years with PCOS | 250 mg/day of magnesium oxide. | The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial.cited 9× |
| magnesium oxide supplement (250 mg/day for 2 months) | Decreases - A significant reduction | serum insulin level | Human | women aged 15-35 years with PCOS | 250 mg/day of magnesium oxide. | The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial.cited 9× |
| magnesium supplements | Decreases - improving | insulin resistance | Human | patients with PCO | 250 mg/day of magnesium oxide. | The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial.cited 9× |
| magnesium plus vitamin E supplements | Decreases - significantly lower | homeostasis model of assessment-insulin resistance | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium plus vitamin E supplements | Increases - higher | quantitative insulin sensitivity check index | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium plus vitamin E supplements | Decreases - significantly lower | serum insulin levels | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium oxide supplementation | No effect - failed to lead to significant differences | first-phase insulin secretion (FPIR) | Human | hypomagnesemic kidney transplant recipients on tacrolimus | Up to 3 times 450 mg magnesium oxide daily (mean 688±237 mg/day). | Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial.cited 19× |
| magnesium and vitamin E co-supplementation | Decreases - led to a significant reduction | homeostatic model of assessment for insulin resistance | Human | women with PCOS | — | The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 19× |
| magnesium and vitamin E co-supplementation | Increases - led to a significant increase | quantitative insulin sensitivity check index | Human | women with PCOS | — | The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 19× |
| magnesium and vitamin E co-supplementation | Decreases - led to a significant reduction | serum insulin levels | Human | women with PCOS | — | The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 19× |
| magnesium and vitamin E co-supplementation | Decreases - significant reduction in | insulin | Human | patients with diabetic foot ulcer (DFU) | — | The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.cited 47× |
| magnesium and vitamin E co-supplementation | Decreases - significant reduction in | insulin resistance | Human | patients with diabetic foot ulcer (DFU) | — | The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.cited 47× |
| magnesium and vitamin E co-supplementation | Increases - significant elevation in | insulin sensitivity | Human | patients with diabetic foot ulcer (DFU) | — | The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.cited 47× |
| Brain food, e.g. L-tryptophan, antioxidative substances, B vitamins and magnesium | Decreases - are thought to be beneficial | obesity, inflammation and insulin resistance | Human | — | Not specified | Has a mixture of amino acids and micronutrients influence on glucose metabolism and dietary fatty acid pattern in chronic psychosocially stressed persons? A pilot study.cited 1× |
| oral magnesium supplementation | Decreases - appeared to decrease | fasting insulin concentrations | Human | overweight individuals | 500 mg elemental Mg/day (as magnesium citrate). | Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals.cited 75× |
| Oral magnesium supplementation | Increases - resulted in increased | insulin resistance | Human | patients with diabetic nephropathy | — | Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial.cited 23× |
| magnesium supplementation | Increases - had greater | insulin resistance | Human | hypomagnesemic patients diagnosed with type 2 diabetes and early-stage nephropathy | — | Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial.cited 23× |
| oral magnesium supplementation (15 mmol/day) | No effect - does not improve | insulin sensitivity | Human | people with insulin-treated type 2 diabetes and low magnesium levels | 15 mmol/day | Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.cited 9× |
| co-supplementation with magnesium and vitamin E | Decreases - resulted in a significant decrease | Insulin | Human | patients with metabolic disorders | — | The effects of magnesium and vitamin E co-supplementation on some cardiovascular risk factors: A meta-analysis.cited 12× |
| magnesium supplementation | Decreases - significantly reduced | fasting insulin level | Human | 1168 participants | — | Association of magnesium consumption with type 2 diabetes and glucose metabolism: A systematic review and pooled study with trial sequential analysis.cited 17× |
| magnesium supplementation | Decreases - significantly reduced | homeostatic model assessment-insulin resistance (HOMA-IR) score | Human | 1168 participants | — | Association of magnesium consumption with type 2 diabetes and glucose metabolism: A systematic review and pooled study with trial sequential analysis.cited 17× |
| magnesium supplementation | No effect - determined an effect on | fasting insulin levels | Human | — | Not specified (differential dosing/shape of magnesium was considered without restriction). | Effect of magnesium supplementation on insulin resistance in humans: A systematic review.cited 48× |
| magnesium supplementation | No effect - may be effective for the treatment | gestational diabetes without taking insulin treatment | Human | women with gestational diabetes | Not available | The efficacy of magnesium supplementation for gestational diabetes: A meta-analysis of randomized controlled trials.cited 3× |
| magnesium supplementation | No effect - no obvious impact | serum insulin | Human | women with gestational diabetes | Not available | The efficacy of magnesium supplementation for gestational diabetes: A meta-analysis of randomized controlled trials.cited 3× |
| magnesium supplementation | No effect - beneficial effects | glucose metabolism and insulin sensitivity | Human | — | Not specified | The role of magnesium in type 2 diabetes: a brief based-clinical review.cited 40× |
| magnesium supplementation | No effect - results are controversial | glucose metabolism and insulin sensitivity | Human | — | Not specified | The role of magnesium in type 2 diabetes: a brief based-clinical review.cited 40× |
| magnesium supplementation | Decreases - significantly reduced | homeostasis model assessment of insulin resistance | Human | women with gestational diabetes | — | Magnesium supplementation for glycemic status in women with gestational diabetes: a systematic review and meta-analysis.cited 5× |
| magnesium supplementation | Decreases - significantly reduced | serum insulin levels | Human | women with gestational diabetes | — | Magnesium supplementation for glycemic status in women with gestational diabetes: a systematic review and meta-analysis.cited 5× |
| magnesium supplementation | Decreases - changes in | homeostasis model of assessment-estimated insulin resistance | Human | women with GDM | 250 mg magnesium oxide daily. | Retracted: Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 50× |
| magnesium supplementation | Increases - changes in | quantitative insulin sensitivity check index | Human | women with GDM | 250 mg magnesium oxide daily. | Retracted: Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 50× |
| magnesium supplementation | Decreases - changes in | serum insulin concentration | Human | women with GDM | 250 mg magnesium oxide daily. | Retracted: Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 50× |
| magnesium supplementation | No effect - did not change significantly | insulin | Human | normomagnesemic subjects with type 2 diabetes | 360 mg elemental magnesium (as magnesium lactate) daily. | No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia.cited 43× |
| magnesium supplementation | No effect - not significant effect | insulin | Human | diabetic and non-diabetic individuals | Not specified in the abstract. | A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control.cited 86× |
| Magnesium supplementation | Decreases - significantly reduced | insulin resistance (HOMA-IR) | Human | patients with metabolic syndrome | — | Synergistic effects of |
| magnesium supplementation | Increases - stimulates | insulin secretion | Molecular | pancreatic cells | Not provided | Participation of Magnesium in the Secretion and Signaling Pathways of Insulin: an Updated Review.cited 17× |
| magnesium supplementation | Increases - improves | insulin sensitivity | Molecular | peripheral tissues | Not provided | Participation of Magnesium in the Secretion and Signaling Pathways of Insulin: an Updated Review.cited 17× |
| magnesium | No effect - participates directly in | insulin sensitivity and signaling in peripheral tissues | Molecular | peripheral tissues | Not provided | Participation of Magnesium in the Secretion and Signaling Pathways of Insulin: an Updated Review.cited 17× |
| magnesium | No effect - plays a vital role in the activity of | intracellular proteins involved in insulin secretion in β-pancreatic cells | Molecular | β-pancreatic cells | Not provided | Participation of Magnesium in the Secretion and Signaling Pathways of Insulin: an Updated Review.cited 17× |
| magnesium | No effect - acting in the phosphorylation of | the receptor tyrosine kinase and the insulin receptor substrates 1, insulin receptor substrates 2, phosphatidylinositol 3-kinase, and protein kinase B | Molecular | — | Not provided | Participation of Magnesium in the Secretion and Signaling Pathways of Insulin: an Updated Review.cited 17× |
| magnesium | No effect - plays an important role in | the secretion and action of insulin | Molecular | — | Not provided | Participation of Magnesium in the Secretion and Signaling Pathways of Insulin: an Updated Review.cited 17× |
| magnesium supplementation | Increases - was shown to improve | insulin sensitivity | HumanMolecular | — | Not specified | Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies.cited 31× |
| magnesium supplementation | Increases - significant rise | quantitative insulin sensitivity check index | Human | subjects with grade 3 DFU | 250 mg magnesium oxide daily. | Magnesium Supplementation and the Effects on Wound Healing and Metabolic Status in Patients with Diabetic Foot Ulcer: a Randomized, Double-Blind, Placebo-Controlled Trial.cited 61× |
| magnesium supplementation | Decreases - significant reductions | serum insulin values | Human | subjects with grade 3 DFU | 250 mg magnesium oxide daily. | Magnesium Supplementation and the Effects on Wound Healing and Metabolic Status in Patients with Diabetic Foot Ulcer: a Randomized, Double-Blind, Placebo-Controlled Trial.cited 61× |
| magnesium supplementation | Decreases - was more beneficial for decreasing | serum insulin | Human | women with GDM | — | Effects of Nutritional Strategies on Glucose Homeostasis in Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.cited 18× |
| magnesium supplementation | Decreases - was superior in decreasing | serum insulin | Human | patients with GDM | — | Effects of Nutritional Strategies on Glucose Homeostasis in Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.cited 18× |
| magnesium supplementation | No effect - no effects | serum lipids, plasma glucose, insulin sensitivity, and low-grade systemic inflammation | Human | overweight and obese subjects | 350 mg daily (three times daily dosing). | Effects of long-term magnesium supplementation on endothelial function and cardiometabolic risk markers: A randomized controlled trial in overweight/obese adults.cited 31× |
| 365 mg of oral magnesium once daily for 3 months | Decreases - significantly decreased | insulin | Human | hypomagnesemic, pre-diabetic and obese patients with mild-to-moderate chronic kidney disease | 365 mg of oral magnesium once daily. | Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study.cited 24× |
| 365 mg of oral magnesium once daily for 3 months | Decreases - significantly decreased | insulin resistance | Human | hypomagnesemic, pre-diabetic and obese patients with mild-to-moderate chronic kidney disease | 365 mg of oral magnesium once daily. | Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study.cited 24× |
| oral supplementation based on myo-inositol (MI), folic acid and liposomal magnesium associated to topical antibiotic therapy (clindamycin gel 1%), systemic antibiotic therapy (clindamycin 300 mg b.i.d. and rifampicin 600 mg daily for 6 weeks) and a normocaloric diet | Decreases - was significantly reduced | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) | Human | subjects with HS and an impaired glucose metabolism (Group A) | MI 2000 mg daily, liposomal magnesium, and folic acid. | An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience.cited 8× |
| magnesium | Increases - enhance | insulin activity | Human | — | Not specified | The Biochemical Role of Macro and Micro-Minerals in the Management of Diabetes Mellitus and its Associated Complications: A Review.cited 14× |
| L-carnitine with magnesium supplementation | No effect - were not affected | insulin levels | Human | NAFLD participants | 2 grams L-carnitine and 150 mg magnesium (CIRRHOS product). | Hepatoprotective effect of combination of L-carnitine and magnesium-hydroxide in nonalcoholic fatty liver disease patients: a double-blinded randomized controlled pilot study. |
| L-carnitine with magnesium supplementation | No effect - were not affected | insulin levels | Human | NAFLD participants | 2 grams L-carnitine and 150 mg magnesium (CIRRHOS product). | Hepatoprotective effect of combination of L-carnitine and magnesium-hydroxide in nonalcoholic fatty liver disease patients: a double-blinded randomized controlled pilot study. |
| Magnesium oxide | Increases - has been shown to improve | insulin resistance | Human | — | Not specified | Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer.cited 6× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - resulted in significant reductions in | homeostatic model of assessment for insulin resistance | Human | patients with GDM | Not specified | Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 35× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Increases - resulted in a significant increase in | quantitative insulin sensitivity check index | Human | patients with GDM | Not specified | Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 35× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - resulted in significant reductions in | serum insulin levels | Human | patients with GDM | Not specified | Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 35× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - significant reductions | homeostatic model of assessment for insulin resistance | Human | women with polycystic ovary syndrome (PCOS) | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| magnesium-zinc-calcium-vitamin D co-supplementation | No effect - had beneficial effects | insulin metabolism | Human | patients with PCOS | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Increases - significant increase | quantitative insulin sensitivity check index | Human | women with polycystic ovary syndrome (PCOS) | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - significant reductions | serum insulin levels | Human | women with polycystic ovary syndrome (PCOS) | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| zinc, copper, selenium, and magnesium | Increases - increase | insulin sensitivity | Human | — | Not specified | Trace element nanoparticles improved diabetes mellitus; a brief report.cited 13× |